The MEQ subscales “Positive Mood” and “Mysticality” are associated with positive PEQ whereas the subscales “Transcendence of Time and Space” and “Ineffability” are not.

Expanding access to MDMA-AT to patients with chronic and severe PTSD will provide substantial health and financial benefits.

Both doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively very similar subjective effects.

MDMA-AT provided to patients with severe or extreme chronic PTSD is cost-saving from a payer’s perspective, while delivering substantial clinical benefit.

Our results suggest that ayahuasca could be used as a potential tool for smoking cessation, and that effects may be mediated by mystical experience.

here we present the top ten available articles exploring psychedelics, serotonin and SSRIs

This paper provides the first comprehensive review of hallucinogens' potential to alleviate symptoms of fear-related disorders

A new study published in the Journal of Humanistic Psychology proposes the mechanism connecting psychedelic use to improved mental health

These findings demonstrate that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months following acute intervention in some patients.

single exposure to 5-MeO-DMT can cause rapid and sustained reductions in symptoms of depression, anxiety and stress.

MDMA-AT for severe PTSD may also lead to subclinical improvements in alcohol use.

Current research doesn’t know much about the special risks and rewards for your generation, according to several scientific experts.

Psilocybin, MDMA, and ketamine can lead to a new sense of self and a release from rigid rules for people with anorexia, bulimia, and binge-eating disorder.

This is an excellent overview of what happened in the field of psychedelics in 2021 with an additional look ahead to what is likely to emerge in 2022.

Low doses of LSD are safe, but produce negligible changes in mood or cognition in healthy volunteers.

LSD changed creativity across modalities and measurement approaches.

Consuming small doses of psilocybin at regular intervals — a process known as microdosing — does not appear to improve symptoms of depression or anxiety

Our review shows that medical risks are often minimal, and that many – albeit not all – of the persistent negative perceptions of psychological risks are unsupported.

Researchers in the field of psychedelics hit the ground running at the turn of the new year.